Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 in Advanced Solid Tumors
NCT04152499Phase 2Active, not recruiting
- Sponsor
- KLUS Pharma
- Start
- Feb 2020
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of sacituzumab tirumotecan in solid tumor, triple-negative breast cancer (TNBC), epithelial ovarian cancer (EOC) and 9 more (11 arms), sponsored by KLUS Pharma. Primary endpoints: Maximum Tolerated Dose at 12 months, Recommended Doses for Expansion at 12 months and 1 more. Started Feb 2020; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
solid tumortriple-negative breast cancer (TNBC)epithelial ovarian cancer (EOC)non-small cell lung cancer (NSCLC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04152499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152499.